10-KPeriod: FY2020

ABBOTT LABORATORIES Annual Report, Year Ended Dec 31, 2020

Filed February 19, 2021For Securities:ABT

Summary

Abbott Laboratories reported strong performance in its 2020 fiscal year, demonstrating resilience and growth across its diversified healthcare segments. The Diagnostics division, in particular, saw a significant surge driven by the successful development and launch of COVID-19 testing solutions, contributing substantially to revenue and profitability. Despite pandemic-related challenges impacting procedural volumes in the Medical Devices segment, areas like Diabetes Care showed robust growth, highlighting the company's diversified product portfolio. The company also maintained a solid financial footing, with increased cash and cash equivalents and a continued commitment to shareholder returns through dividend payments. Strategic investments in research and development, particularly in diagnostics and medical devices, position Abbott for sustained long-term growth. Management's focus on operational efficiency and product innovation, even amidst global health challenges, underscores the company's strategic execution and adaptability.

Financial Highlights

52 data points
Beta

Revenue

$34.61B

56.6% Gross Margin

Net Income

$4.50B

13.0% Net Margin

EPS (Diluted)

$2.50

Total Assets

$72.55B

Cash & Equivalents

$6.84B

Free Cash Flow

$5.72B

Financial Statements
Beta
Revenue$34.61B
Cost of Revenue$15.00B
Gross Profit$19.61B
R&D Expenses$2.42B
SG&A Expenses$9.70B
Operating Expenses$29.25B
Operating Income$5.36B
Interest Expense$546.00M
Net Income$4.50B
EPS (Basic)$2.52
EPS (Diluted)$2.50
Shares Outstanding (Basic)1.77B
Shares Outstanding (Diluted)1.79B

Key Highlights

  • 1Strong revenue growth driven by the Diagnostics segment, significantly boosted by COVID-19 testing solutions ($3.884 billion in sales).
  • 2Medical Devices segment faced COVID-19 headwinds affecting cardiovascular and neuromodulation procedures, but Diabetes Care achieved double-digit growth.
  • 3Established Pharmaceuticals and Nutritional Products segments demonstrated resilience, with growth in key emerging markets and strong performance in adult nutritionals, respectively.
  • 4Increased cash and cash equivalents to $6.838 billion, up from $3.860 billion in the prior year, reflecting strong operational cash flow.
  • 5Abbott increased its quarterly dividend by 25% to $0.45 per share, demonstrating commitment to shareholder returns.
  • 6Operating earnings margin improved to 15.5% in 2020, up from 14.2% in 2019, driven by diagnostics sales and cost management.
  • 7The company actively managed its debt, maintaining an investment-grade credit rating (A by S&P, A3 by Moody's).

Frequently Asked Questions

The primary driver of Abbott's revenue growth in 2020 was its Diagnostics segment, which saw a significant increase due to the successful development and sale of COVID-19 diagnostic tests, generating approximately $3.884 billion in sales. This surge more than offset the negative impact of reduced routine diagnostic testing volumes caused by the pandemic.

The COVID-19 pandemic had a mixed impact. The Diagnostics segment experienced substantial growth due to COVID-19 testing. The Medical Devices segment faced challenges with reduced procedural volumes affecting cardiovascular and neuromodulation products, though Diabetes Care saw strong growth. The Established Pharmaceuticals and Nutritional Products segments generally showed resilience.

As of December 31, 2020, Abbott had $18.7 billion in long-term debt. However, the company also maintained a strong liquidity position with $6.838 billion in cash and cash equivalents, an increase from $3.860 billion in the previous year. Abbott's credit ratings remained strong at A (S&P) and A3 (Moody's), indicating a solid financial foundation.

Abbott continues to invest significantly in research and development across its segments. In 2020, R&D expenses were $2.4 billion. The company plans to focus on driving market adoption and geographic expansion of its diagnostic systems, enhancing its medical device portfolio (especially in diabetes care, structural heart, and electrophysiology), growing its nutritionals business globally, and expanding its pharmaceutical business in emerging markets.